From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Tuesday's episode, health-care analyst David Williamson discusses Novartis (NVS 1.10%), which has teamed up with Goldman Sachs to re-examine its businesses, and potentially sell off some of its divisions. David looks at Novartis' various divisions and discusses how the ones potentially on the chopping block contribute to the company as a whole, and he also compares this possibility with some other recent major Big Pharma spinoff deals.
